Select a Region North America

Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review

How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better recommendations and less pressure for the US payer community. Unfortunately, ‘reactive-response’ is more common than ‘enterprise engagement.’


Managing an ICER review is a time critical process with multiple checkpoints and opportunities to engage in the process. The process will define a transparent flow. However, the large number of steps combined with speed or review requires that the manufacturer has plans and all data available long before the review begins…

Learn more about our Health Technology Assessment Products & Capabilities!

Contact us with your questions and data needs, and an expert will follow up shortly.

“Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review”
141.60 KB
Author Team

NAVLIN Insights gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market access questions. Learn…